Trial Outcomes & Findings for Testosterone Replacement in Older Men and Atherosclerosis Progression (NCT NCT00287586)
NCT ID: NCT00287586
Last Updated: 2017-06-29
Results Overview
B-mode carotid artery images for IMT were acquired from the far wall of the distal centimeter of the right carotid artery with high-resolution ultrasound equipment. IMT is used as a predictor of the incidence of cardiovascular events. An increase in the IMT thickness is associated with a higher incidence of cardiovascular events. Less thickening is best. Change is expressed in millimeters (mm).
COMPLETED
PHASE4
308 participants
Baseline and Month 36
2017-06-29
Participant Flow
Participant milestones
| Measure |
Testosterone
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Overall Study
STARTED
|
156
|
152
|
|
Overall Study
Intent-to-treat: Received Study Drug
|
155
|
151
|
|
Overall Study
COMPLETED
|
111
|
100
|
|
Overall Study
NOT COMPLETED
|
45
|
52
|
Reasons for withdrawal
| Measure |
Testosterone
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Overall Study
Withdrew Consent
|
19
|
30
|
|
Overall Study
Lost to Follow-up
|
5
|
4
|
|
Overall Study
Death
|
2
|
3
|
|
Overall Study
Elevated Hematocrit
|
3
|
0
|
|
Overall Study
Rash
|
3
|
0
|
|
Overall Study
Elevated Prostate Specific Antigen
|
2
|
0
|
|
Overall Study
Stroke
|
2
|
0
|
|
Overall Study
Myocardial Infarction
|
1
|
0
|
|
Overall Study
Lower Urinary Tract Symptoms
|
1
|
0
|
|
Overall Study
Cognitive Impairment
|
1
|
0
|
|
Overall Study
Pancreatic Cancer
|
1
|
3
|
|
Overall Study
Sleep Apnea
|
1
|
0
|
|
Overall Study
Shoulder Pain
|
1
|
0
|
|
Overall Study
Inappropriate Behaviour with Staff
|
1
|
0
|
|
Overall Study
Nonadherence
|
1
|
1
|
|
Overall Study
Enrolled in Another Study
|
1
|
0
|
|
Overall Study
Major Depression
|
0
|
2
|
|
Overall Study
Lung Cancer
|
0
|
2
|
|
Overall Study
Elevated IPSS Score
|
0
|
1
|
|
Overall Study
Retroperitoneal Cancer
|
0
|
1
|
|
Overall Study
Mastodynia and Gynecomastia
|
0
|
1
|
|
Overall Study
Mood Swings and Irritability
|
0
|
1
|
|
Overall Study
Bradycardia
|
0
|
1
|
|
Overall Study
Itchy Swollen Eyes
|
0
|
1
|
|
Overall Study
Recurrent Melanoma
|
0
|
1
|
Baseline Characteristics
Testosterone Replacement in Older Men and Atherosclerosis Progression
Baseline characteristics by cohort
| Measure |
Testosterone
n=155 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=151 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
Total
n=306 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
66.9 years
STANDARD_DEVIATION 5.0 • n=99 Participants
|
68.3 years
STANDARD_DEVIATION 5.3 • n=107 Participants
|
67.6 years
STANDARD_DEVIATION 5.2 • n=206 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
155 Participants
n=99 Participants
|
151 Participants
n=107 Participants
|
306 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with data available at the given time-point.
B-mode carotid artery images for IMT were acquired from the far wall of the distal centimeter of the right carotid artery with high-resolution ultrasound equipment. IMT is used as a predictor of the incidence of cardiovascular events. An increase in the IMT thickness is associated with a higher incidence of cardiovascular events. Less thickening is best. Change is expressed in millimeters (mm).
Outcome measures
| Measure |
Testosterone
n=155 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=151 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in Common Carotid Artery Intima-Media Thickness (IMT)
Baseline
|
0.877 mm
Standard Deviation 0.210
|
0.879 mm
Standard Deviation 0.199
|
|
Change From Baseline in Common Carotid Artery Intima-Media Thickness (IMT)
Change at Month 36
|
0.036 mm
Standard Deviation 0.059
|
0.033 mm
Standard Deviation 0.077
|
PRIMARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with data available at the given time-point.
A multiple detector computed tomography (MDCT) scan was performed. Proximal coronary arteries were visualized, and at least 30 consecutive images were obtained at 3-mm intervals. Coronary calcium was defined as a plaque of at least 3 contiguous pixels (area, 1.02 mm\^2) with a density of more than 130 Hounsfield units.The lesion score was calculated by multiplying lesion area by a density factor derived from Hounsfield units. The Agatston method was used to determine the total calcium score by summing the lesion scores from the left main, left anterior descending, circumflex, and right coronary arteries. The Agatston score is the measure of calcification in arteries expressed on continuous scale with "0" value (better) indicating no calcification and score above 400 (worse) indicating high calcification. There is no upper limit for this measure. A positive change from baseline indicates a worsening.
Outcome measures
| Measure |
Testosterone
n=155 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=151 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in Coronary Artery Calcium Score
Baseline
|
451.78 score on a scale
Standard Deviation 715.41
|
508.31 score on a scale
Standard Deviation 694.87
|
|
Change From Baseline in Coronary Artery Calcium Score
Change at Month 36
|
103.61 score on a scale
Standard Deviation 289.45
|
124.54 score on a scale
Standard Deviation 208.42
|
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with data available at the given time-point.
Laboratory tests included in the lipid profile were Total Cholesterol, High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C) and Triglycerides.Lower values for Total Cholesterol, LDL-C are better and a negative change from Baseline indicates improvement. Higher values for HDL-C are better and a positive change from Baseline indicates improvement.
Outcome measures
| Measure |
Testosterone
n=155 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=151 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in Lipid Profiles
HDL-C, Change at Month 36
|
0.18 mg/dL
Standard Deviation 9.69
|
2.00 mg/dL
Standard Deviation 11.08
|
|
Change From Baseline in Lipid Profiles
LDL-C, Baseline
|
115.64 mg/dL
Standard Deviation 35.18
|
109.66 mg/dL
Standard Deviation 31.86
|
|
Change From Baseline in Lipid Profiles
LDL-C, Change at Month 36
|
-11.24 mg/dL
Standard Deviation 26.80
|
-13.92 mg/dL
Standard Deviation 30.80
|
|
Change From Baseline in Lipid Profiles
Triglycerides, Baseline
|
142.695 mg/dL
Standard Deviation 87.93
|
138.95 mg/dL
Standard Deviation 76.37
|
|
Change From Baseline in Lipid Profiles
Triglycerides, Change at Month 36
|
-19.41 mg/dL
Standard Deviation 73.69
|
-12.62 mg/dL
Standard Deviation 84.62
|
|
Change From Baseline in Lipid Profiles
Total Cholesterol, Baseline
|
187.15 mg/dL
Standard Deviation 42.09
|
183.44 mg/dL
Standard Deviation 36.68
|
|
Change From Baseline in Lipid Profiles
Total Cholesterol, Change at Month 36
|
-14.88 mg/dL
Standard Deviation 35.92
|
-12.56 mg/dL
Standard Deviation 33.90
|
|
Change From Baseline in Lipid Profiles
HDL-C, Baseline
|
47.11 mg/dL
Standard Deviation 11.97
|
48.71 mg/dL
Standard Deviation 14.21
|
SECONDARY outcome
Timeframe: Three yearsPopulation: No analysis was performed. No funds were left to cover the costs of the assays for inflammation biomarkers.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Three yearsPopulation: No analysis was performed. Although blood pressure measurements were standardized within a trial site, there is a possibility that measurement techniques might have varied across the three trial sites over the trial's long duration. For this reason we decided not to include blood pressure data in the results.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with cognitive baseline data and data available at the given time-point.
Cognitive Function was assessed by Complex Figure (Immediate) and (Delayed). The Complex Figure Test consists of three tasks: copy, immediate recall, and delayed recall. Participants were presented with a complex design and then asked to draw the same figure. Subsequently, they were instructed to draw what they remembered immediately, and after a 30 minute delay. Scoring was based on the number of correct items for a total possible score of 0 (worst) to 36 (Best). A positive change from Baseline indicates improvement. A negative change from Baseline indicates a worsening.
Outcome measures
| Measure |
Testosterone
n=140 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=140 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in Complex Figure (Immediate) and Complex Figure (Delayed)
Complex Figure:Immediate, Baseline
|
20.95 correct items
Standard Deviation 6.50
|
20.31 correct items
Standard Deviation 6.20
|
|
Change From Baseline in Complex Figure (Immediate) and Complex Figure (Delayed)
Complex Figure:Immediate, Change at Month 36
|
-1.25 correct items
Standard Deviation 4.90
|
-0.24 correct items
Standard Deviation 6.11
|
|
Change From Baseline in Complex Figure (Immediate) and Complex Figure (Delayed)
Complex Figure:Delayed, Baseline
|
20.28 correct items
Standard Deviation 6.08
|
19.75 correct items
Standard Deviation 6.11
|
|
Change From Baseline in Complex Figure (Immediate) and Complex Figure (Delayed)
Complex Figure:Delayed, Change at Month 36
|
-0.49 correct items
Standard Deviation 5.20
|
-0.24 correct items
Standard Deviation 5.74
|
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with cognitive baseline data and data available at the given time-point.
Cognitive Function was assessed by the Paragraph Recall Test (Delayed). In the Paragraph Recall Test, participants were read two short paragraphs and asked to recall them immediately and after a 30 minute delay, using the exact words that were read aloud. Scoring was based on the number of items correctly recalled. More items correctly recalled is best and a positive change from Baseline indicates improvement.
Outcome measures
| Measure |
Testosterone
n=140 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=140 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in Paragraph Recall Test (Delayed)
Paragraph: Delayed, Baseline
|
13.69 correct items
Standard Deviation 6.37
|
13.57 correct items
Standard Deviation 6.12
|
|
Change From Baseline in Paragraph Recall Test (Delayed)
Paragraph:Delayed, Change at Month 36
|
2.15 correct items
Standard Deviation 6.05
|
1.72 correct items
Standard Deviation 4.82
|
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with cognitive baseline data and data available at the given time-point.
Cognitive function was assessed by the Buschke Selective Reminding Test. In the Buschke Selective Reminding Test, participants were read 12 words and asked to recall as many words as possible. Subsequent trials included only those words that were not recalled in the preceding trial. Individuals were also asked to recall the list 30 minutes later. To assess phonemic and category fluency, participants were asked to name as many items from a given category as possible in 1 minute. Higher number of correct items is best and a positive change from Baseline indicates improvement.
Outcome measures
| Measure |
Testosterone
n=140 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=140 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in the Buschke Selective Reminding Test (Delayed)
Buschke Total Correct Delayed, Baseline
|
8.00 correct items
Standard Deviation 2.80
|
7.76 correct items
Standard Deviation 2.69
|
|
Change From Baseline in the Buschke Selective Reminding Test (Delayed)
Buschke Total Correct Delayed, Change at Month 36
|
0.47 correct items
Standard Deviation 2.46
|
0.85 correct items
Standard Deviation 2.21
|
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with cognitive baseline data and data available at the given time-point.
Cognitive function was assessed by the Verbal Fluency Test. Participants were asked to name as many letters from a given category as possible in 1 minute. Higher number of letters is best and a positive change from Baseline indicates improvement.
Outcome measures
| Measure |
Testosterone
n=140 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=140 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in the Verbal Fluency Test
Baseline
|
26.96 letters
Standard Deviation 10.25
|
27.02 letters
Standard Deviation 8.97
|
|
Change From Baseline in the Verbal Fluency Test
Change at Month 36
|
2.86 letters
Standard Deviation 8.84
|
1.77 letters
Standard Deviation 7.35
|
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with cognitive baseline data and data available at the given time-point.
Cognitive function was assessed by the Category Fluency Test. Participants were asked to name as many items from a given category as possible. Higher number of items named is best and a positive change from Baseline indicates improvement.
Outcome measures
| Measure |
Testosterone
n=140 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=140 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in the Category Fluency Test
Category Fluency, Baseline
|
18.07 items
Standard Deviation 5.61
|
18.01 items
Standard Deviation 5.62
|
|
Change From Baseline in the Category Fluency Test
Category Fluency, Change at Month 36
|
2.25 items
Standard Deviation 6.81
|
0.37 items
Standard Deviation 6.77
|
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with cognitive baseline data and data available at the given time-point.
Cognitive function was assessed by the Stroop Interference Test. In the Stroop Interference Test, participants were presented with a word list of colors printed in ink of a color different from how the printed word read. Participants were instructed to read aloud the color of the ink in which a word was printed, while not verbalizing the word itself. The time in seconds that the items were correctly identified was recorded. Less time is better and a negative change from Baseline indicates improvement.
Outcome measures
| Measure |
Testosterone
n=140 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=140 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in the Stroop Interference Test
Stroop Interference, Baseline
|
55.64 seconds
Standard Deviation 15.60
|
56.84 seconds
Standard Deviation 15.85
|
|
Change From Baseline in the Stroop Interference Test
Stroop Interference, Change at Month 36
|
-1.07 seconds
Standard Deviation 14.48
|
0.99 seconds
Standard Deviation 16.10
|
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with cognitive baseline data and data available at the given time-point.
Cognitive function was assessed by the Trail Making Test B. Trail Making Test B involved participants connecting numbers (1-13) and letters (A-L) alternately (1-A, 2-B, etc) on a piece of paper as quickly as possible. Scores represent the time it takes the participant to complete the test. Less time is best and a negative change from Baseline indicates improvement. A positive change from Baseline indicates a worsening.
Outcome measures
| Measure |
Testosterone
n=140 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=140 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in the Trail Making Test B
Trails B, Baseline
|
98.52 seconds
Standard Deviation 42.40
|
97.57 seconds
Standard Deviation 31.82
|
|
Change From Baseline in the Trail Making Test B
Trails B, Change at Month 36
|
3.88 seconds
Standard Deviation 34.15
|
11.26 seconds
Standard Deviation 40.61
|
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with baseline physical function data and data available at the given time-point.
Maximal voluntary strength of the lower and upper extremities was assessed using the one repetition maximum (1-RM) method for the seated leg press and chest press exercises. Participants were positioned with standardized seat position and foot placement that allowed 90° of knee flexion for the leg press exercise. Seat height and handle position was standardized for the chest press. Participants were familiarized with the exercises, practiced the technique and completed a 5-minute warm-up. The 1-RM procedure consisted of a warm up set with 5 to 8 repetitions at a resistance set to about 50% of the participant's estimated 1-RM and progressed with increasing loads interspersed with standardized rest periods until the participant was able to perform only one full-range-of-motion repetition.
Outcome measures
| Measure |
Testosterone
n=135 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=121 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in Chest Press Strength and Leg Press Strength
Chest Press Strength, Baseline
|
516.99 newton
Standard Deviation 133.37
|
513.83 newton
Standard Deviation 104.92
|
|
Change From Baseline in Chest Press Strength and Leg Press Strength
Chest Press Strength, Change at Month 36
|
-12.73 newton
Standard Deviation 54.20
|
-26.20 newton
Standard Deviation 40.88
|
|
Change From Baseline in Chest Press Strength and Leg Press Strength
Leg Press Strength, Baseline
|
2270.37 newton
Standard Deviation 424.81
|
2233.74 newton
Standard Deviation 416.06
|
|
Change From Baseline in Chest Press Strength and Leg Press Strength
Leg Press Strength, Change at Month 36
|
-37.26 newton
Standard Deviation 230.42
|
-65.33 newton
Standard Deviation 251.94
|
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with baseline physical function data and data available at the given time-point.
Physical Function was evaluated using two tests of stair climb power using an indoor 12-step staircase. One test consisted of ascending the 12-steps as rapidly as possible without running (unloaded stair climb) while the second test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags (loaded stair climb). Time to ascend the stairs was measured electronically with a digital clock and switch mats placed at the base of the steps and on the 12th step. Power in watts is calculated by the following: \[body weight (kilograms) \* distance (meters)/ (time/60)\] /6.12. A negative change from Baseline indicates improvement.
Outcome measures
| Measure |
Testosterone
n=135 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=121 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change From Baseline in Unloaded Stair Climb Power and Loaded Stair Climb Power
Unloaded Stair Climb Power, Baseline
|
536.33 watts
Standard Deviation 134.40
|
535.78 watts
Standard Deviation 125.70
|
|
Change From Baseline in Unloaded Stair Climb Power and Loaded Stair Climb Power
Unloaded Stair Climb Power, Change at Month 36
|
-8.17 watts
Standard Deviation 71.60
|
-12.89 watts
Standard Deviation 64.28
|
|
Change From Baseline in Unloaded Stair Climb Power and Loaded Stair Climb Power
Loaded Stair Climb Power, Baseline
|
581.24 watts
Standard Deviation 148.73
|
594.84 watts
Standard Deviation 150.28
|
|
Change From Baseline in Unloaded Stair Climb Power and Loaded Stair Climb Power
Loaded Stair Climb Power, Change at Month 36
|
-8.44 watts
Standard Deviation 70.56
|
-12.76 watts
Standard Deviation 63.13
|
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with data available at the given time-point.
IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (6 questions), orgasmic function (2 questions), sexual desire (2 questions), intercourse satisfaction (3 questions), and overall sexual satisfaction (2 questions). Each question was answered on a 5-point scale from 1 to 5 (best) with a total possible score range of 0 to 75 with higher scores representing better function. A positive change from Baseline indicates improvement.
Outcome measures
| Measure |
Testosterone
n=155 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=151 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Erectile Function, Baseline
|
18.33 score on a scale
Standard Deviation 10.11
|
18.67 score on a scale
Standard Deviation 10.64
|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Erectile Function, Change at Month 36
|
-0.15 score on a scale
Standard Deviation 7.40
|
-0.80 score on a scale
Standard Deviation 7.55
|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Orgasmic Function, Baseline
|
7.37 score on a scale
Standard Deviation 3.61
|
6.38 score on a scale
Standard Deviation 3.86
|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Orgasmic Function, Change at Month 36
|
-0.65 score on a scale
Standard Deviation 3.35
|
0.24 score on a scale
Standard Deviation 3.44
|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Sexual Desire, Baseline
|
6.89 score on a scale
Standard Deviation 2.04
|
6.58 score on a scale
Standard Deviation 2.19
|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Sexual Desire, Change at Month 36
|
0.18 score on a scale
Standard Deviation 1.94
|
0.07 score on a scale
Standard Deviation 1.87
|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Intercourse Satisfaction, Baseline
|
8.32 score on a scale
Standard Deviation 5.92
|
8.14 score on a scale
Standard Deviation 5.94
|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Intercourse Satisfaction, Change at Month 36
|
0.05 score on a scale
Standard Deviation 4.56
|
-0.71 score on a scale
Standard Deviation 4.11
|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Overall Satisfaction, Baseline
|
6.24 score on a scale
Standard Deviation 2.84
|
6.12 score on a scale
Standard Deviation 2.64
|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Overall Satisfaction, Change at Month 36
|
0.40 score on a scale
Standard Deviation 2.77
|
0.81 score on a scale
Standard Deviation 2.54
|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Total Score, Baseline
|
48.48 score on a scale
Standard Deviation 21.09
|
49.67 score on a scale
Standard Deviation 23.25
|
|
Change in Sexual Function as Assessed by the International Index of Erectile Function (IIEF)
Total Score, Change at Month 36
|
0.22 score on a scale
Standard Deviation 15.54
|
-0.39 score on a scale
Standard Deviation 15.32
|
SECONDARY outcome
Timeframe: Baseline and Month 36Population: All participants from the Intent-to-treat population, all randomized and treated participants, with data available at the given time-point.
The SF-36 measures 8 domains of the QoL: physical function, bodily pain, vitality, role limitations due to physical problems, general health perceptions, emotional well-being, social function, and role limitations due to emotional problems. Each domain is scored separately from 0 to 100 with higher scores representing better health-related QoL. The Overall Score is the average of the individual domain scores. A negative change from Baseline indicates improvement.
Outcome measures
| Measure |
Testosterone
n=155 Participants
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=151 Participants
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Energy/Fatigue, Baseline
|
69.92 score on a scale
Standard Deviation 18.47
|
71.21 score on a scale
Standard Deviation 14.67
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Energy/Fatigue, Change at Month 36
|
-1.45 score on a scale
Standard Deviation 13.40
|
-0.46 score on a scale
Standard Deviation 12.57
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Emotional Well-Being, Baseline
|
82.67 score on a scale
Standard Deviation 12.64
|
83.17 score on a scale
Standard Deviation 11.38
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Emotional Well-Being, Change at Month 36
|
-1.16 score on a scale
Standard Deviation 14.76
|
0.91 score on a scale
Standard Deviation 11.60
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Role Limitations/Emotional Problems, Baseline
|
90.00 score on a scale
Standard Deviation 23.21
|
89.08 score on a scale
Standard Deviation 26.04
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Role Limitations/Emotional Problems,Change
|
3.51 score on a scale
Standard Deviation 32.69
|
-9.09 score on a scale
Standard Deviation 34.00
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Social Functioning, Baseline
|
90.42 score on a scale
Standard Deviation 16.17
|
92.89 score on a scale
Standard Deviation 13.06
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Social Functioning, Change at Month 36
|
-3.29 score on a scale
Standard Deviation 22.64
|
-4.83 score on a scale
Standard Deviation 14.06
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Physical Functioning, Baseline
|
82.00 score on a scale
Standard Deviation 20.15
|
83.28 score on a scale
Standard Deviation 18.79
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Physical Functioning, Change at Month 36
|
-3.82 score on a scale
Standard Deviation 21.20
|
-2.39 score on a scale
Standard Deviation 21.09
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Role Limitations/Physical Health, Baseline
|
80.00 score on a scale
Standard Deviation 30.81
|
88.79 score on a scale
Standard Deviation 21.55
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Role Limitations,/Physical Health, Change
|
-1.97 score on a scale
Standard Deviation 24.23
|
-9.66 score on a scale
Standard Deviation 34.61
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Pain, Baseline
|
82.83 score on a scale
Standard Deviation 17.29
|
82.24 score on a scale
Standard Deviation 15.84
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Pain, Change at Month 36
|
-7.96 score on a scale
Standard Deviation 14.81
|
-5.97 score on a scale
Standard Deviation 17.90
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
General Health, Baseline
|
74.17 score on a scale
Standard Deviation 19.51
|
76.72 score on a scale
Standard Deviation 15.18
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
General Health, Change at Month 36
|
-0.53 score on a scale
Standard Deviation 11.90
|
-3.75 score on a scale
Standard Deviation 14.59
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Overall Score, Baseline
|
81.50 score on a scale
Standard Deviation 14.12
|
83.42 score on a scale
Standard Deviation 12.45
|
|
Change in Health Quality of Life (QoL) as Assessed by Short Form 36 (SF-36)
Overall Score, Change at Month 36
|
-2.08 score on a scale
Standard Deviation 11.88
|
-4.40 score on a scale
Standard Deviation 12.24
|
Adverse Events
Testosterone
Placebo
Serious adverse events
| Measure |
Testosterone
n=155 participants at risk
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=151 participants at risk
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
General disorders
Death
|
0.65%
1/155
|
4.0%
6/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pulmonary carcinoma complications
|
0.00%
0/155
|
0.66%
1/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic cancer
|
0.00%
0/155
|
0.66%
1/151
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/155
|
0.66%
1/151
|
|
Cardiac disorders
Angina pectoris
|
0.65%
1/155
|
2.0%
3/151
|
|
Infections and infestations
Appendicitis
|
0.00%
0/155
|
0.66%
1/151
|
|
Surgical and medical procedures
Appendectomy
|
0.00%
0/155
|
0.66%
1/151
|
|
Infections and infestations
Bacterial septicemia
|
0.00%
0/155
|
0.66%
1/151
|
|
Surgical and medical procedures
Triple by-pass surgery
|
0.00%
0/155
|
0.66%
1/151
|
|
Surgical and medical procedures
Coronary artery bypass graft
|
0.00%
0/155
|
0.66%
1/151
|
|
General disorders
Chest pain
|
0.65%
1/155
|
0.66%
1/151
|
|
Infections and infestations
Colitis with abscess and fistula
|
0.00%
0/155
|
0.66%
1/151
|
|
Gastrointestinal disorders
Colonic diverticulitis
|
0.00%
0/155
|
0.66%
1/151
|
|
Surgical and medical procedures
Complete ankle replacement surgery
|
0.00%
0/155
|
0.66%
1/151
|
|
Cardiac disorders
Congestive heart failure
|
0.00%
0/155
|
0.66%
1/151
|
|
Cardiac disorders
Congestive heart failure exacerbation
|
0.00%
0/155
|
0.66%
1/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung mass
|
0.00%
0/155
|
0.66%
1/151
|
|
Infections and infestations
E.coli infection
|
0.00%
0/155
|
0.66%
1/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioma
|
0.00%
0/155
|
0.66%
1/151
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
0.00%
0/155
|
0.66%
1/151
|
|
Renal and urinary disorders
Renal artery stenosis
|
0.00%
0/155
|
0.66%
1/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanoma
|
0.00%
0/155
|
0.66%
1/151
|
|
Infections and infestations
Meningitis not otherwise specified (NOS)
|
0.00%
0/155
|
0.66%
1/151
|
|
Infections and infestations
Bacteriemia
|
0.00%
0/155
|
0.66%
1/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.00%
0/155
|
0.66%
1/151
|
|
Injury, poisoning and procedural complications
Mugged
|
0.00%
0/155
|
0.66%
1/151
|
|
Cardiac disorders
Pulseless electrical activity (PEA) cardiac arrest
|
0.00%
0/155
|
0.66%
1/151
|
|
Infections and infestations
Pneumonia
|
0.65%
1/155
|
0.66%
1/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung cancer reaccurence
|
0.00%
0/155
|
0.66%
1/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
1.9%
3/155
|
1.3%
2/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung pulmonary nodule
|
0.00%
0/155
|
0.66%
1/151
|
|
Cardiac disorders
Slient myocardial infarction
|
0.00%
0/155
|
0.66%
1/151
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/155
|
0.66%
1/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.00%
0/155
|
0.66%
1/151
|
|
Injury, poisoning and procedural complications
Coronary angiogram resulted in 2 occluded vessels
|
0.00%
0/155
|
0.66%
1/151
|
|
Surgical and medical procedures
Coronary stent procedure
|
0.65%
1/155
|
0.66%
1/151
|
|
Gastrointestinal disorders
Upper gastrointestinal bleeding
|
0.00%
0/155
|
0.66%
1/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
1.3%
2/155
|
0.00%
0/151
|
|
Cardiac disorders
Acute posterior myocardial infarction
|
0.65%
1/155
|
0.00%
0/151
|
|
Surgical and medical procedures
Angioplasty
|
1.3%
2/155
|
0.00%
0/151
|
|
Infections and infestations
Aspiration pneumonia
|
0.65%
1/155
|
0.00%
0/151
|
|
Infections and infestations
Bilateral toe gangrene
|
0.65%
1/155
|
0.00%
0/151
|
|
Infections and infestations
Cellulites on right foot and calf
|
0.65%
1/155
|
0.00%
0/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cerebellar neoplasm
|
0.65%
1/155
|
0.00%
0/151
|
|
Investigations
Elevated blood pressure
|
0.65%
1/155
|
0.00%
0/151
|
|
Surgical and medical procedures
Complete left knee replacement surgery
|
0.65%
1/155
|
0.00%
0/151
|
|
Cardiac disorders
Coronary artery disease
|
0.65%
1/155
|
0.00%
0/151
|
|
Cardiac disorders
Coronary heart disease
|
0.65%
1/155
|
0.00%
0/151
|
|
Nervous system disorders
Cerebrovascular accident (CVA)
|
1.9%
3/155
|
0.00%
0/151
|
|
General disorders
Exertional chest pains
|
0.65%
1/155
|
0.00%
0/151
|
|
Nervous system disorders
Herniated free fragment with right lumbar radiculopathy
|
0.65%
1/155
|
0.00%
0/151
|
|
General disorders
Leg pain
|
0.65%
1/155
|
0.00%
0/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Localized prostate adeno-carcinoma
|
0.65%
1/155
|
0.00%
0/151
|
|
Cardiac disorders
Myocardial infarction
|
1.3%
2/155
|
0.00%
0/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm left kidney
|
0.65%
1/155
|
0.00%
0/151
|
|
Vascular disorders
Saphenous vein graft occlusion
|
0.65%
1/155
|
0.00%
0/151
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic tumor
|
0.65%
1/155
|
0.00%
0/151
|
|
Surgical and medical procedures
Quadruple by-pass surgery
|
0.65%
1/155
|
0.00%
0/151
|
|
Nervous system disorders
Right hemispheric subacute stroke
|
0.65%
1/155
|
0.00%
0/151
|
|
Surgical and medical procedures
Right knee re-placement surgery
|
0.65%
1/155
|
0.00%
0/151
|
|
Cardiac disorders
Second-degree atrioventricular heart block
|
0.65%
1/155
|
0.00%
0/151
|
|
Surgical and medical procedures
Dual chamber pace maker placement
|
0.65%
1/155
|
0.00%
0/151
|
Other adverse events
| Measure |
Testosterone
n=155 participants at risk
Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
|
Placebo
n=151 participants at risk
Participants received placebo-matching testosterone gel daily for 3 years.
|
|---|---|---|
|
Investigations
Elevated Prostate-Specific Antigen (PSA)
|
10.3%
16/155
|
6.0%
9/151
|
|
Infections and infestations
Upper respiratory infection
|
7.7%
12/155
|
7.9%
12/151
|
|
Investigations
Elevated hematocrit (HCT)
|
5.2%
8/155
|
0.00%
0/151
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place